Digital Therapeutics’ Promising Start


Pear Therapeutics, a Boston-based digital therapeutic company, rang in the New Year with $64mm in Series C funding from Temasek, Novartis, 5AM Ventures, Arboretum Ventures, and more. This announcement came shortly after reSET-O, their prescription digital therapeutic designed to treat opioid use disorder, became the first software-only digital therapeutic cleared by the FDA. Pear will continue to develop digital therapeutics for Multiple Sclerosis (MS) and Schizophrenia with Novartis. With their recent funding, the “software based disease treatments” company hopes to globalize their reSET products and further fund their other clinical-stage developments.

Pear Therapeutics is not the only digital therapeutic company benefiting from the heightened interest in software as clinical treatment. Last week, Click Therapeutics announced a partnership with Ostuka America to create a new digital therapeutic for major depressive disorder (MDD). The Japanese Pharmaceutical company intends to invest $300mm into the initiative with the goal of delivering evidence-based cognitive therapies to a broader population of patients with MDD.

This wave of investment in digital therapeutics by pharmaceutical companies shows no signs of slowing and indicates a promising future for software-based treatments to become mainstream medicine.